Amalgamated Bank Sells 143 Shares of Krystal Biotech, Inc. (NASDAQ:KRYS)

Amalgamated Bank decreased its position in Krystal Biotech, Inc. (NASDAQ:KRYS) by 1.9% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 7,434 shares of the company’s stock after selling 143 shares during the quarter. Amalgamated Bank’s holdings in Krystal Biotech were worth $1,353,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of KRYS. Swiss National Bank grew its stake in Krystal Biotech by 0.8% in the first quarter. Swiss National Bank now owns 36,200 shares of the company’s stock valued at $6,441,000 after purchasing an additional 300 shares in the last quarter. Sei Investments Co. raised its position in Krystal Biotech by 128.3% during the first quarter. Sei Investments Co. now owns 33,752 shares of the company’s stock worth $6,005,000 after acquiring an additional 18,968 shares in the last quarter. ProShare Advisors LLC raised its position in Krystal Biotech by 9.0% during the first quarter. ProShare Advisors LLC now owns 5,865 shares of the company’s stock worth $1,044,000 after acquiring an additional 486 shares in the last quarter. State Board of Administration of Florida Retirement System lifted its stake in Krystal Biotech by 18.5% in the first quarter. State Board of Administration of Florida Retirement System now owns 7,307 shares of the company’s stock valued at $1,300,000 after acquiring an additional 1,140 shares during the last quarter. Finally, Scout Investments Inc. bought a new position in shares of Krystal Biotech in the 1st quarter valued at about $8,976,000. Institutional investors and hedge funds own 86.29% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on the company. HC Wainwright reissued a “buy” rating and set a $221.00 price target on shares of Krystal Biotech in a research report on Tuesday, November 5th. Stifel Nicolaus raised their price target on Krystal Biotech from $204.00 to $220.00 and gave the company a “buy” rating in a report on Wednesday, September 11th. William Blair upgraded shares of Krystal Biotech to a “strong-buy” rating in a report on Friday, August 30th. Citigroup raised their target price on shares of Krystal Biotech from $204.00 to $206.00 and gave the stock a “neutral” rating in a research note on Tuesday, November 5th. Finally, Chardan Capital upped their price target on shares of Krystal Biotech from $153.00 to $208.00 and gave the company a “buy” rating in a research note on Monday, August 5th. One research analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, Krystal Biotech has a consensus rating of “Buy” and an average price target of $197.00.

Krystal Biotech Trading Down 1.6 %

Shares of NASDAQ:KRYS opened at $184.22 on Thursday. The firm has a 50 day moving average of $181.31 and a 200-day moving average of $181.36. The stock has a market capitalization of $5.30 billion, a PE ratio of 104.08 and a beta of 0.82. Krystal Biotech, Inc. has a 12 month low of $96.73 and a 12 month high of $219.34.

Krystal Biotech (NASDAQ:KRYS) last issued its quarterly earnings results on Monday, November 4th. The company reported $0.91 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.84 by $0.07. Krystal Biotech had a return on equity of 7.54% and a net margin of 21.68%. The company had revenue of $83.84 million for the quarter, compared to analyst estimates of $82.94 million. During the same quarter last year, the company posted ($0.67) EPS. The company’s revenue for the quarter was up 879.9% compared to the same quarter last year. On average, research analysts predict that Krystal Biotech, Inc. will post 2.97 EPS for the current fiscal year.

Insider Activity

In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of the business’s stock in a transaction on Thursday, September 12th. The shares were sold at an average price of $197.76, for a total transaction of $4,944,000.00. Following the sale, the insider now owns 1,500,882 shares of the company’s stock, valued at approximately $296,814,424.32. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. 14.10% of the stock is currently owned by corporate insiders.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).